xolo, known for its high-performance bioprinters, uses its proprietary Xolography technology to print complex cellular structures quickly and accurately. Rousselot Biomedical, an expert in biomedical gelatins, offers the X-Pure range, recognized for its exceptional purity and consistency. X-Pure GelMA (gelatin methacrylate), when used in bioinks, is designed to deliver exceptional stable and reproducible printing results while supporting optimal cell growth.
“We are dedicated to accelerating medical research by bridging the gap between research and clinical application,” said Tanja Vervust, Director of Rousselot Biomedical, “Our X-Pure range, available in GMP and research-equivalent grades, is ideal for translational research. We are thrilled to collaborate with xolo, a start-up at the forefront of biomedical innovation.”
Stephan Kuehr, Chief Commercial Officer of <w:sdt id="-1316791463" sdttag="goog_rdk_11">x</w:sdt>olo, added: “Our customers expressed a need for GelMA bio-ink with consistent purity, ready to be used with our volumetric printers, allowing our clients to fully focus on their research without concerns about quality issues. We’re excited to collaborate with Rousselot, which shares our vision for enabling faster, more reliable bioprinting solutions. Together, we can meet these needs by providing high-quality, ready-to-use bioinks that perfectly complement our advanced printing technology, helping researchers push the boundaries of biomedical innovation.”
This agreement marks an important step in the field of bioprinting, creating new opportunities for researchers by providing access to materials of outstanding quality and reliability.